TFF Pharmaceuticals (NASDAQ:TFFP – Get Rating) had its price objective cut by HC Wainwright from $22.00 to $4.00 in a research note published on Thursday, The Fly reports.
Separately, Jonestrading assumed coverage on shares of TFF Pharmaceuticals in a research report on Wednesday, March 22nd. They set a buy rating and a $7.00 target price for the company.
TFF Pharmaceuticals Trading Down 7.1 %
Shares of NASDAQ TFFP opened at $0.55 on Thursday. The firm’s 50 day moving average price is $0.66 and its 200-day moving average price is $0.89. TFF Pharmaceuticals has a 52-week low of $0.48 and a 52-week high of $6.73.
Insider Buying and Selling
Institutional Trading of TFF Pharmaceuticals
Institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC purchased a new position in TFF Pharmaceuticals during the 4th quarter worth approximately $1,826,000. DRW Securities LLC acquired a new position in TFF Pharmaceuticals in the fourth quarter valued at about $1,050,000. Vanguard Group Inc. lifted its position in TFF Pharmaceuticals by 6.5% in the first quarter. Vanguard Group Inc. now owns 864,983 shares of the company’s stock valued at $5,458,000 after buying an additional 52,813 shares during the last quarter. Sepio Capital LP lifted its position in TFF Pharmaceuticals by 4.9% in the fourth quarter. Sepio Capital LP now owns 330,600 shares of the company’s stock valued at $347,000 after buying an additional 15,540 shares during the last quarter. Finally, Gagnon Securities LLC lifted its position in TFF Pharmaceuticals by 255.3% in the first quarter. Gagnon Securities LLC now owns 221,207 shares of the company’s stock valued at $152,000 after buying an additional 158,943 shares during the last quarter. 16.46% of the stock is currently owned by institutional investors.
TFF Pharmaceuticals Company Profile
TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
- Get a free copy of the StockNews.com research report on TFF Pharmaceuticals (TFFP)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.